The burden of sexually transmitted diseases in developing countries is enormous. The World Health Organisation (WHO) estimates that, in 1995, 333 million new cases of syphilis, gonorrhoea, chlamydial infection, and tichomoniasis occurred.' Disease burden is highest in sub-Saharan Africa, where the combined incidence of these four infections is estimated at 254 per 1000 population at risk. ' Similarly, the HIV epidemic is of greatest magnitude in developing countries, it being estimated that 93% of the 27.9 million people infected with HIV by mid 1996 lived in developing countries.2 SubSaharan Africa again suffers disproportionately, comprising 68% of the people infected with HIV worldwide. These two epidemics have substantial impact. Globally, STDs collectively rank second in importance among diseases for which intervention is possible among women aged The report by Hayes and his colleagues stands out as an insightful summary of many of the issues that surround community randomised trials and will be of immense interest and value to those researching STD interventions in developing countries. It discusses the important role that community randomised trials have in studying STD control strategies, outlines the different strategies that exist and that might be considered, provides a very useful section that discusses in depth some of the key epidemiological and statistical issues in the design and analysis of such trials, and closes by outlining diagnostic methods, treatment regimens, and ethical issues of relevance to such trials.
Only one of the trials that is discussed has been published to date. The Mwanza (Tanzania) trial6 created a huge stir when its findings were published in 1995 and considerable hope for effective HIV prevention in developing countries was generated. In a very pragmatic way the investigators tested the impact of syndromic management for STDs delivered in primary care clinics on HIV incidence. They showed a 42% reduction in HIV incidence, but without any substantial impact on STD prevalence. Unfortunately, implementation of this apparently simple and cost effective intervention has been slow and difficult in many settings. The Rakai (Uganda) study, which is much more complex, is a trial of mass treatment of entire communities with modern, expensive STD drugs. Prevalence of STDs is reported to have fallen, following on the initial treatment rounds, and results of the impact on HIV incidence are eagerly awaited. The Masaka (Uganda) study is comparing syndromic management with information and education campaigns.
As two of these large and expensive trials are testing the impact of STD syndromic management on HIV incidence, and as their results are likely to have a significant impact on public health policy and, hopefully, practice, it is timely to reconsider the place and likely impact of syndromic management for STDs in control of the STD and HIV epidemics in developing countries.
Syndromic management is the only feasible way to treat patients in developing countries who present to a health facility with an STD. 
